Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cold reactive lymphocytotoxic sera from patients with systemic lupus erythematosus and their relatives were found to react with lymphocyte antigens that cluster in normal families. These antigens do not correlate with HLA-A or -B antigens in families, suggesting that they are not related to Ir genes. Further work is indicated to determine whether these antigens are controlled by several genes or involve viral products on the cell surface.
 ...
PMID:Antilymphocyte antibodies in systemic lupus erythematosus: familial clustering of lymphocyte antigens. 30 39

Forty-four patients with systemic lupus erythematosus (SLE) were classified as mild or more severe on the basis of renal biopsy changes and the degree of proteinuria. The HLA phenotype A2 plus B7 was associated with the mild cases, while A1 plus B8 was associated with more severe disease. These findings suggest that immunogenetic factors are important in determining the severity of SLE and that combinations of HLA-A and -B locus antigens may be significant in HLA disease associations.
 ...
PMID:HLA in systemic lupus erythematosus: influence on severity. 69 14

Patients with mixed connective tissue disease (MCTD, n = 32) or systemic lupus erythematosus (SLE, n = 60) were typed for HLA-A, B, C, Dw, and DR antigens. All patients with SLE fulfilled at least four criteria of SLE and the patients with MCTD met the criteria proposed by Alarcon-Segovia (1989). The presence of antibodies to Sm was not considered as an exclusion for MCTD. In the patients with SLE, Dw3, DR3, and the associated B8 and A1 antigens were increased, whereas in the patients with MCTD an increased frequency of Dw4 was found (45 v 18% in controls v 14% in SLE). Of the subtypes of DR4, Dw4 was present in all but one of the DR4 positive patients. The frequency of DR4 in patients with MCTD (52%) differed significantly from that of controls (28%). The strong association of MCTD to one DR4 subtype was further seen in the significantly increased frequency of the B15, DR4 combination. Thus the genetic background seems to be different in patients with MCTD from that in patients with SLE. This could partly explain the clinical differences between these diseases.
 ...
PMID:Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. 154 38

In order to verify the hypothesis that Italian patients with systemic lupus erythematosus (SLE) may be immunogenetically distinct from SLE patients born in other regions, we investigated the HLA class I and II antigens and their relation with the various autoantibodies characteristic of the disease in an Italian SLE population. Forty-four SLE patients were typed for HLA-A, -B, -C, -DR and -DQ antigens; sera from the same patients were tested for the presence of antibodies to the nuclear or cytoplasmic antigens Ro/SSA, La/SSB, Sm and RNP (ENA). Results of HLA typing showed that the frequencies of DR3 and DQw2 were increased in patients compared with controls. Analysis of the correlations between HLA antigens and anti-ENA antibodies showed that both DQw2 and DR3 were increased in patients with anti-Ro and/or antiLa antibodies, while in patients with anti-Sm and/or antiRNP antibodies the DQw2 and DR4 were found to be increased. Only DQw2 was found to be significantly increased in anti-ENA positive patients. These results might suggest that Italian patients with SLE are, at least in part, different from lupus patients living in other geographical areas and suggest the association of DQw2 with the autoantibody response to ENA in SLE.
 ...
PMID:HLA antigens in Italian patients with systemic lupus erythematosus: evidence for the association of DQw2 with the autoantibody response to extractable nuclear antigens. 195 98

100 consecutive Chinese patients with SLE were recruited for study of HLA-A, B and DR antigen. Clinical and serological parameters were analysed with respect to the HLA antigens. B5 was associated with presence of other autoimmune diseases (thyrotoxicosis, myasthenia gravis, diabetes mellitus, corrected p less than 0.025); absence of malar rash (corrected p less than 0.025); B35, with male sex (corrected p less than 0.025); DR2 with anti-Ro (anti-SSA) antibody (p less than 0.05). Previous study of association with B13, B17 was not present in our cohort. Except for malar rash, subclassification of disease status with respect to HLA antigen did not reveal significant association.
 ...
PMID:Immunogenetics in Chinese patients with SLE. 203 Nov 54

We report on the production of tumor necrosis factor (TNF)-alpha and TNF-beta by mitogen-activated peripheral blood lymphocytes or enriched monocyte subpopulations from human leukocyte antigen (HLA)-typed healthy subjects. The results indicate that HLA-DR2- and DQw1-positive donors frequently exhibit low production of TNF-alpha, whereas DR3- and DR4-positive subjects show high levels of TNF-alpha production. No correlation between TNF-alpha levels and HLA-A, -B, and -C genotype was found. The relevance of this quantitative polymorphism to the genetic predisposition to lupus nephritis in systemic lupus erythematosus (SLE) patients was investigated. DR2, DQw1-positive SLE patients show low levels of TNF-alpha inducibility; this genotype is also associated with an increased incidence of lupus nephritis. DR3-positive SLE patients, on the other hand, are not predisposed to nephritis, and these patients have high TNF-alpha production. DR4 haplotype is associated with high TNF-alpha inducibility and is negatively correlated with lupus nephritis. These data may help explain the strong association between HLA-DR2, DQw1 in SLE patients and their susceptibility to nephritis.
 ...
PMID:Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. 210

The frequency of the HLA-A, -B and -DR alloantigens was studied in 74 unselected, consecutive, unrelated Greek patients with systemic lupus erythematosus (SLE) and the results were compared with those of healthy controls (380 for the class I antigens and 154 for the class II antigens). No statistically significant differences were noted between patients and controls regarding the prevalence of any class II antigen. Furthermore, no such differences were observed between our 36 anti-Ro (SSA) positive and the rest of our SLE patients. However, the coexistence of anti-Ro (SSA) and anti-La (SSB) antibodies (9 patients) correlated significantly with HLA-B8, whereas the haplotype HLA-B8DR3 was more common in the anti-Ro (SSA) positive patients than in the rest-although the difference did not reach statistical significance. The combination of high anti-ds-DNA and low C4 serum levels correlated with absence of HLA-DR5. Our findings, while in agreement with those of certain previous studies, are somewhat different from those of others. The differences may at least partly be related to variations in the control populations employed. On the other hand some of the differences, in accordance with other peculiarities of Greeks with connective tissue disease, emphasize the role of racial and/or ethnic background in the HLA-association of various autoimmune diseases and the fact that the detectable HLA alloantigens in certain diseases modify disease and autoantibody expression rather than being responsible for the autoimmune process itself.
 ...
PMID:HLA alloantigens in Greek patients with systemic lupus erythematosus. 234 34

Previous studies of patients with systemic lupus erythematosus (SLE) have shown an increased frequency of certain major histocompatibility complex (MHC) markers, including HLA-DR2, DR3, and C4AQ0 (C4A-null), in Caucasian patients. However, most of these studies were of randomly selected, unrelated patients; families were not included, and haplotypes were not determined. In order to define more accurately the possible role of MHC genes in lupus susceptibility, HLA-A, B, C, and DR, as well as BF, C2, C4A, C4B, and GLO, markers were determined in 62 Caucasian patients of known ethnic background, and in the members of their families. The distributions of extended haplotypes (fixed combinations of HLA-B, DR, and complotype alleles), fragments thereof, and individual alleles were determined in SLE patients and controls. The MHC distributions in all patients were compared with haplotypes in a normal Caucasian population. There were no statistically significant differences between the frequencies of any MHC marker, fragment, or extended haplotype in the patients compared with the controls. The patients were categorized into 2 groups of European ancestry (English/Irish; other Europeans), and each group was compared with a group of ethnically matched controls. There was a statistically significantly increased frequency of the alleles C4AQ0 and DR3 and the complotype SC01 in SLE patients of English/Irish descent as compared with ethnically matched controls. The increase in C4AQ0 and DR3 could be accounted for by the fact that they were part of the extended haplotype [HLA-B8;SC01;DR3] and/or its fragment (SC01;DR3). No increase in any MHC marker was observed in the other patients.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. 236 33

The expression of HLA class I was assessed on erythrocytes by haemagglutination with monoclonal antibodies to monomorphic epitopes on the heavy and light (beta 2-microglobulin) chains. Previously, enhancement of HLA class I expression was observed on erythrocytes of many patients with systemic lupus erythematosus (SLE) and chronic lymphatic leukaemia (CLL), and we have now tested erythrocytes from patients (and 130 normal controls) with other auto-immune diseases and renal and haematological disorders. The striking enhancement in patients with SLE and CLL was confirmed. A significant increase in expression was also observed in aplastic anaemia patients following bone marrow transplantation and in renal patients with primary glomerulonephritis who had received a transplant. No class I was expressed by erythrocytes from many patients with inherited haemoglobinopathies and high reticulocyte counts, which suggests that the enhancement in SLE patients cannot be accounted for by immature or young erythrocyte populations. The distribution of HLA-A and -B types in the patients with enhanced class I expression did not relate to those antigens previously detected more frequently on erythrocytes, B7(Bga), B17(Bgb), A28(Bgc), B8 or A10, and the enhancement was not associated with any particular HLA types.
 ...
PMID:Erythroid HLA class I expression in 300 patients with haematological, renal and rheumatological disorders. 239 73

1. Presensitization in first cadaver kidney recipients can lead to increased risk of graft failure by hyperacute rejection, or delayed function up to 1 month. Fifty percent of the hyperacute rejections occurred in nonsensitized recipients. The number of "classical" hyperacute rejections was small, but they have been occurring at a rate of about 10 per year. 2. One-year graft survival of nonsensitized recipients of first and second cadaver transplants was about the same. One-year graft survival of broadly sensitized recipients of first and second cadaver transplants was 8% lower than those who were moderately sensitized. One-year graft survival of second cadaver transplants in all sensitized recipients was significantly lower (9-13%) than in first cadaver transplants. 3. The proportion of transfused recipients was 89% in parous females, 84% in nulliparous females, and 80% in males. Pretransplant transfusions also increased sensitization of males and females awaiting their first kidney transplant. Females were significantly more sensitized than males, whether they were transfused or not. 4. One-year graft survival rates of transfused recipients were 5-9% higher than nontransfused recipients. Highly sensitized patients who were transfused had the same 1-year graft survival as nontransfused, nonsensitized recipients. 5. Patients in Southern California waiting for a second transplant were more broadly sensitized than those waiting for a first kidney. A higher proportion of sensitized patients were waiting more than 3 years for a second transplant than for a first. 6. Patients waiting for a first transplant were more sensitized than those transplanted for the first time. The highest number of waiting or transplanted patients was blood group O. 7. A significantly greater proportion of sensitized patients with blood groups A and B was waiting than those with blood type O. The type O patients were transplanted at the same rate as they entered the waiting list. It is possible that sensitized type O patients were being discouraged from entering the waiting list. 8. A significantly smaller proportion of broadly sensitized SLE patients was waiting for a first transplant since 1988, although SLE patients were more broadly sensitized compared to those with other diseases and waiting since 1981 to 1987. This further confirms that many SLE patients are transplanted, as their sensitization is more often associated with autoantibody. 9. The highest proportion of currently sensitized recipients occurred in the transplants with 0 mismatches for the HLA-A,B specificities of the donor kidney.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Sensitization and crossmatching in renal transplantation. 248 6


1 2 3 4 5 Next >>